Omanta, a San Francisco startup in Y Combinator's Summer 2026 batch, launched a service on August 4 that assigns a dedicated scientific team to an individual patient, drawing together medical records, genomics and published evidence. The company has not disclosed pricing.
The pitch rests on a gap the founders say they see: patients who have exhausted standard treatments rarely have anyone continuously connecting their biology to new research. That is the rationale given on the company's leadership page, not a quantified market finding.
What Omanta does
The company calls the offering a personalized research lab. Its launch post, which RuntimeWire covered the same day, described a system that merges a patient's records, genomic data and scientific evidence into a single research effort.
Y Combinator's description points to patients who have exhausted standard options, want to prepare for a recurrence, or live with an unresolved diagnosis, and it names oncology, rare disease and undiagnosed conditions. Forbes contributor Dasha Shunina reported on September 3 that the company is starting with oncology, a narrower focus than YC's list suggests.
"We organize a dedicated scientific team around each patient to understand their disease at the molecular level," said Ranad Humeidi, co-founder and chief science officer, in a LinkedIn post about the Forbes coverage.
For clinicians, the company's page promises a scientific rationale, a list of uncertainties and further questions to raise with the treating team. Scope, timeline and initial deliverables, it says, are agreed before work begins, and treating clinicians keep responsibility for care. "You lead the care. We carry the science," the page reads.
A roadmap, with caveats
Omanta's homepage describes an evolving roadmap that spans surveillance, early molecular changes, progression and investigational options, including N-of-1 therapy development (a treatment designed for a single patient) where appropriate.
The site's interfaces are illustrative. A displayed 5,000-sample cohort and its molecular measurements are demonstration content, not customer counts, dataset scale or patient outcomes. The site also says its therapeutic modeling is not a response prediction or a treatment recommendation.
No clinical results were identified in the materials reviewed. Those materials also leave out pricing, insurance coverage, reimbursement arrangements, contract structure and who ultimately pays.
The founders
Alfredo Gonzalez is co-founder and CEO. His YC profile describes experience across personalized vaccines, immunotherapies and radioligands, a class of drugs that deliver radiation to tumors. GitLab co-founder Sid Sijbrandij wrote on LinkedIn that "the CEO, Alfredo Gonzalez, was a bioinformatician on my team and did an amazing job."
Sijbrandij also said he is not involved with Omanta. Omanta and YC promotional material link Gonzalez's earlier work to Sijbrandij's complete remission, while Forbes attributes that account more cautiously to the team. Either way, it is experience from an individual case, not controlled evidence of Omanta's efficacy.
Humeidi's listed affiliations are the Broad Institute, Harvard University and the University of Pennsylvania. Her company biography says she began in synthetic organic chemistry and co-led a Broad Institute fellowship that translated discoveries into companies. A YC announcement reproduced on LinkedIn says the two founders met eight years before the launch, doing early CRISPR cancer research at the Broad. The employment dates were not independently established.
As for the team, YC's founder profiles, checked November 7, list six people, with Diana Hu as primary partner. The AI Front Page had reported four on August 3.
Funding picture is murky
Omanta has not announced a funding round, and the databases that track such things disagree. CB Insights lists $500,000 from Y Combinator dated August 1, 2026, structured as a convertible note, a loan that converts to equity later. Fast AI Jobs lists a $500,000 seed round on the same date. Dealroom shows $125,000 in September 2026. Company-specific closing documents were not located.
Competitors and open questions
RuntimeWire named Genomate Health, which ranks precision-oncology treatment options, as an adjacent offering. Foundation Medicine sells genomic profiling, including FoundationOne CDx and FoundationOne Liquid CDx, though its diagnostics are not an equivalent to a dedicated research-team service. Project IMPACT-AI, led by Stanford's Sylvia Plevritis and UCSF's Julian Hong, integrates records, pathology, radiology and molecular profiles for cancer care, but it is an academic initiative.
RuntimeWire's Ryan Merket identified the central execution questions as evidence provenance, the accuracy of record ingestion, clinical validation and how conflicts between studies get resolved. That was analysis at launch, not testing of Omanta's product.
Public interest is plain enough. Doomers recorded 998,518 views on the launch post as of October 9. It is a third-party engagement count, and it says nothing about patient adoption or efficacy.
Sijbrandij's separate LinkedIn post and an August 10 blog post by Eric Binnion show only that he considered Omanta. Neither establishes a signed engagement, a payment or an outcome.
